�ݺ�ߣ

Weisberg Consulting, LLC

15
Benedict
Crescent

Tel:
(732)
773-‐4332

Basking
Ridge,
NJ
07920

Email:
iraweis@optonline.net

About Us
  Weisberg
ConsulGng
derives
its
experGse
with
an
extensive
experience
in

business
and
corporate
development
as
well
as
building
brands
and
companies

both
in
the
United
States
as
well
as
internaGonal
markets.

  Structured
along
the
lines
of
a
pharmaceuGcal
company,
we
have
four
areas
of

specialty:

  Corporate
and
Business
Development

  Market
intelligence

  Brand
management

  Brand
and
corporate
strategy.

  The
integraGon
of
these
specialGes
allows
for
the
development
of
stakeholder-‐
driven
and
fact-‐based
strategies.
This
approach
has
repeatedly
generated

substanGal
and
sustainable
growth,
even
in
mature
markets
–
providing
clarity,

control
and
conﬁdence
in
strategy
to
improve
both
brand
and
business

performance.

Key Transactions

M&A/Out-‐licensing
Deals

  IniGated
and
closed
on
a
$105
million
transacGon
with
Cowen
Healthcare
Royalty
in
which
we

moneGzed
the
royalty
stream
of
a
key
product

  NegoGated
several
off-‐shore
licensing
deals
on
several
key
products

  Raised
iniGal
funding
for
the
development
of
a
new
company
involved
in
an
innovaGve

cardiovascular
therapeuGc.

  Led
acquisiGon
of
a
business
from
Baxter
Healthcare
enabling
company
to
be
first
entrant
into

$400
million
US
market.

  Generated
proceeds
of
$30
million
in
IPO
providing
capital
for
growth
and
product
development.

  Concluded
an
iniGal
round
of
funding
with
a
mid-‐west
venture
capital
group
for
$3.5
million;

leading
the
efforts
to
raise
an
addiGonal
$9
million
in
a
Series
A
financing
for
a
cardiovascular

product

  Out-‐licensed
a
GI
opportunity
to
a
specialty
pharmaceuGcal
company
–
Deal
Value:
$150
million

  Out-‐licensed
an
oncology/immune-‐enhancement
biologic
to
a
mid-‐sized
pharmaceuGcal
company

–
Deal
Value:
$200
million

  Divested
the
viral
tesGng
business
of
AvenGs
Behring
to
NaGonal
GeneGcs
InsGtute,
subsidiary
of

LabCorp

Key Transactions
Other
Deals

  IniGated
and
closed
on
a
partnering
arrangement
to
enhance
product

development
and
add
new
products
into
the
development
pordolio

  Led
negoGaGons
on
the
acquisiGon
of
a
cardiovascular
opportunity
–
Deal

Value:
$500
million

  Led
the
development
of
a
global
recombinant
albumin
business
valued
in

excess
of
$750
million;
negoGated
out-‐licensing
agreements
with
a

number
of
major
pharmaceuGcal
companies

  NegoGated
a
Licensing
Agreement
with
the
leading
global
medical
device

company
–
Deal
Value:
$650
million

  NegoGated
a
Supply
and
DistribuGon
Agreement
that
resulted
a
net
in

excess
of
$100
million
over
several
years

Key Transactions
Other
Deals
(cont’d)

  NegoGated
a
licensing
and
development
agreement
with
a
leading
pulmonary

delivery
device
ﬁrm
with
a
deal
value
of
$350
million

  NegoGated
a
licensing
and
development
agreement
for
a
specialty
medical

product
valued
at
$500
million

  NegoGated
agreement
for
the
distribuGon
of
acquired
products
in
US.

  Developed
exclusive
global
contract
manufacturing
agreement
with
European

company,

avoiding
expense
of
$75
million
for
construcGon
of
manufacturing
facility.

  Managed
transfer
of
proprietary
technology
to
European
manufacturer,

completed
in
less
than

twelve
months
at
75%
of
originally
budgeted
cost.

  Led
the
negoGaGon
of
a
License
Agreement
for
a
monoclonal-‐based
pladorm

opportunity
Deal
Value:
$350
million

The Licensing Process
Our
goal
is
to
idenGfy
licensors
for
hard
to
license

products.
This
is
done
by
conducGng
the
following

analyses:

  What
strategic
gaps
in
pipeline
or
pordolio
need
to

be
ﬁlled
to
by
the
candidate
licensor?

  What
are
the
underlying
dynamics
of
the
product

to
be
licensed?

  How
will
potenGal
licensors
relate
to
the
product?

  Which
markeGng
levers
will
drive
growth
the

product?

The Licensing Process
Our
approach
will
provide
a
structural

understanding
of
the
product
to
be
licensed.
We

structure,
source
and
analyze
informaBon
in
a

manner
that
provides
a
360o
perspecBve
of
the

product.
Such
a
perspecBve
drives
decision
making

differently.
We
will
provide
clarity
and
transparency

on
brand
performance
issues
as
well
as
provide

insight
into
untapped
sources
of
business.

The
success
of
any
brand
is
based
on
a
number

of
interconnected
elements.
We
will
idenBfy

which
of
these
levers
drives
performance
of

your
brand
and
provides
effecBve
control
over

its
execuBon.

Our
iteraBve
and
highly
dynamic
modeling
approach
enables
you

to
explore,
test
and
analyze
a
range
of
plausible
strategic
scenarios

in
a
risk-‐free
environment.

Our
custom
built
tools
provide
a
high

degree
of
confidence
in
the
chosen
strategy
for
building
superior

brand
performance.

�ݺ�ߣ

Weisberg Consulting Introduction

More Related Content

Weisberg Consulting Introduction